Fig. 3.

Cumulative response rates over time (investigator-assessed) for a complete response and b MRD status. Note: The term “induction therapy” refers to BR. The induction phase is defined as the first six cycles of the study, when BR is given along with study drug (ibrutinib or placebo) as combination therapy. The end of the induction phase is the last dose of B or R+30 days. BR bendamustine and rituximab, CR complete response, CRi CR with incomplete bone marrow recovery, MRD minimal residual disease. Note: Percentages are based on the number of patients in the intent-to-treat analysis set in each treatment arm